KADUNA BUSINESSMAN DRAGS EX FIANCEE’S FATHER TO COURT, DEMANDS DOWRY REFUND. (PHOTO).

-
Image
Kaduna businessman drags ex fiancee’s father to court, demands dowry refund A businessman, Nasiru Dayyabu, on Wednesday, dragged the father of his ex-fiance, Mallam Sani Direba, to Shari’a Court II sitting at Magajin Gari, Kaduna over N260,000 dowry. The complainant had joined Direba in the suit against two brothers demanding a refund of N250, 000 dowry and N10,000 introduction money he paid to marry his daughter. Represented by his counsel, Mr Sani Sunusi, the complainant told the court that he sent his people from Karaye, Kano State to Kaduna in 2025, to seek for the defendant’s daughter’s hand in marriage. “We paid the dowry and the introduction money (kudin gausuwa) and were waiting for them to set a date for the wedding,” he said. “Unfortunately, the lady’s father called to inform us that they have cancelled the marriage.” The counsel said the complainant had asked for the refund of his money since Sept. 2025 but all the efforts he made proved abortive. He claimed that his client ...
Post a Comment

FDA APPROVES CLINICAL TRIALS FOR PIG KIDNEY TRANSPLANTS IN HUMANS. (PHOTO).

-


 FDA Approves Clinical Trials for Pig Kidney Transplants in Humans


The US Food and Drug Administration has greenlit clinical trails for organ transplants from genetically modified pigs. The study led by United Therapeutics Corp will begin with six patients facing end-stage renal disease — eventually being expanded to include 50 kidney failure patients. The first transplant is expected to occur in mid-2025.

According to a statement released by the company on Monday, patients will receive a UKidney transplant followed by a 24-week post-transplant follow-up period. Participants will continue to be followed for the rest of their lives — including for survival, UKidney function, and monitoring for zoonotic infections4 — during this time.


The first cohort will comprise of six transplants at two centers — with a 12-week waiting period between the first and second transplants. Data will be reviewed after this group of patients reaches at least 12 weeks post-transplant in order to determine whether the study should continue. 

United Therapeutics has also indicated plants to engage with the FDA after the first six transplants are completed. If safety and efficacy results are supportive, the sample size will be increased to a total of up to 50 participants to enable the study to support registration, with additional transplant centers expected to be added to the study.


The studies could be a breakthrough for people needing a kidney transplant. More than 37 million Americans are estimated to have chronic kidney disease, according to 2021 data from the US Centers for Disease Control and Prevention. Patients in need of a kidney transplant can wait for as long as five years before the procedure, with a risk of complications arising during that time. An estimated 12 people die each day while waiting for a kidney, according to the National Kidney Foundation.

Comments

Post a Comment